{{Rsnum
|rsid=705381
|Gene=PON1
|Chromosome=7
|position=95324637
|Orientation=plus
|GMAF=0.2388
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PON1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 3.3 | 96.7
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 33.8 | 51.0 | 15.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 50.0 | 37.8 | 12.2
| LWK | 35.5 | 47.7 | 16.8
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs705381]], also known as -161C/T and -162A/G, is a SNP in the upstream promoter region of the [[PON1]] gene.  (The assumption of equivalence between these names is based on the results of searching for [[rs705381]] in the [http://www.hugenavigator.net/HuGENavigator/startPageMapper.do Variant Name Mapper].)

{{PMID|17199131}} In a study of 101 mostly Caucasian patients prescribed the atypical antipsychotic [[risperidone]], carriers of a [[rs705381]](C) allele were less likely to gain significant weight compared to [[rs705381]](T;T) carriers, as assessed by physiogenomic analysis of corresponding weight profiles. Two other SNPs, [[rs8179183]] and [[rs6837793]], were also significantly associated with weight profiles in these patients.

{{PMID|15060281)}} In a study of 461 participants in the HERITAGE cohort (172 African-American, 289 Caucasian), the combination of [[rs705381]] with "PON-126" (RS ID unknown) were found to significantly contribute to trait-anxiety scores.  The authors also cite another paper, {{PMID|12525679}}, which found that this SNP accounts for 2.4% of the variation in [[PON1]] expression.  Which allele correlates  with increased trait-anxiety scores and/or reduced [[PON1]] expression is unclear.

HapMap frequencies for this SNP seem dubious.  They list [[rs705381]](T;T) as being at or near 100% for the population groups reported by SNPedia.  However, the raw data at HapMap for this SNP are largely no-call (e.g. CEU: NN=87, TT=82, CT=3).  The other diversity studies listed at [http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=705381#Diversity dbSNP] show C as the more common allele (e.g. AFD_AFR_PANEL: CC=47.8%, CT=39.1%, TT=13.0%).  Anecdotal data submitted by participants at 23andme also show C as being more common (CC=4, CT=1, TT=2).  The diversity data have therefore been removed until these discrepancies can be resolved.

{{PMID|18618303|OA=1
}} A common haplotype within the PON1 promoter region is associated with sporadic ALS.

{{PMID|19321847|OA=1
}} A large-scale international meta-analysis of paraoxonase gene polymorphisms in sporadic ALS.

{{PMID|21223581|OA=1
}} Association analysis of PON2 genetic variants with serum paraoxonase activity and systemic lupus erythematosus.

{{PMID Auto
|PMID=23356507
|Title=Association between paraoxonase gene and stroke in the Han Chinese population
|OA=1
}}

{{PMID Auto
|PMID=24448003
|Title=Methylmercury exposure, PON1 gene variants and serum paraoxonase activity in Eastern James Bay Cree adults
}}

{{PMID Auto
|PMID=22884547
|Title=Association analysis of PON polymorphisms in sporadic ALS in a Chinese population.
}}

{{PMID Auto
|PMID=22956172
|Title=Regulatory regions of the paraoxonase 1 (PON1) gene are associated with neovascular age-related macular degeneration (AMD).
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}